TABLE 2.
Results of the glucose-dependent arginine stimulation test in Caucasian postmenopausal women who had NGT at baseline but developed IGT (n = 26) or maintained NGT (n = 27) during the 12-year follow-up
| Maintaining NGT | Developing IGT | |
|---|---|---|
| n | 27 | 26 |
| Fasting insulin (pmol/l) | 48 ± 2.5 | 60 ± 8* |
| Fasting glucose (mmol/l) | 4.6 ± 0.1 | 4.7 ± 0.1 |
| Insulin at second arginine injection (pmol/l) | 221 ± 18 | 212 ± 9 |
| Glucose at second arginine injection (mmol/l) | 14.2 ± 0.1 | 14.2 ± 0.1 |
| Insulin at third arginine injection (pmol/l) | 448 ± 39 | 508 ± 36 |
| Glucose at third arginine injection (mmol/l) | 28.3 ± 0.2 | 28.8 ± 0.3 |
| AIR1 (pmol/l) | 335 ± 33 | 394 ± 106 |
| AIR2 (pmol/l) | 1,001 ± 119 | 1,018 ± 126 |
| AIR3 (pmol/l) | 994 ± 149 | 1,081 ± 162 |
| SlopeAIR (pmol/mmol) | 62 ± 8.1 | 64 ± 8.0 |
| Fasting glucagon (ng/l) | 66 ± 4.6 | 64 ± 4.2 |
| Glucagon at second arginine injection (ng/l) | 54 ± 4.6 | 53 ± 4.6 |
| Glucagon at third arginine injection (ng/l) | 42 ± 2.9 | 41 ± 2.0 |
| AGR1 (ng/l) | 84 ± 7.8 | 86 ± 11.8 |
| AGR2 (ng/l) | 36 ± 4.0 | 49 ± 6.2* |
| AGR3 (ng/l) | 24 ± 3.6 | 27 ± 4.1 |
| SlopeAGR (ng/mmol) | −5.3 ± 0.5 | −4.2 ± 0.5* |
| Glucose infusion rate during min 60–120 of the clamp (μmol/kg/min) | 60 ± 3 | 52 ± 3* |
| Insulin sensitivity (nmol · kg−1 · min−1 · pmol) | 89 ± 3 | 80 ± 4* |
Data are means ± SE.
*
P < 0.05 as probability level of random difference between the groups.